Jean-Michel Boers joins PhRMA’s board
Jean-Michel Boers, Boehringer Ingelheim’s U.S. country managing director, president and CEO, has been appointed to the board of directors of the Pharmaceutical Research and Manufacturers of America.
“The U.S. market plays a pivotal role when it comes to pharmaceutical innovation for better patient outcomes. The appointment of Jean-Michel is important for Boehringer Ingelheim in continuing our efforts to help advance current healthcare and industry policy framework in the U.S.”, said Carinne Brouillon, member of the board of managing directors at Boehringer Ingelheim with responsibility for the Human Pharma business unit.
Boers took over his current position at Boehringer Ingelheim U.S. in June, having previously served as president of Boehringer Ingelheim Pharmaceuticals, where he was responsible for the U.S. commercial and medical organization. Boers joined Boehringer Ingelheim in 1998, and advanced through various leadership roles in corporate and operating units. He earned a master’s degree in social and economic history from the University of Nijmegen in the Netherlands and an MBA from the University of Texas.
“PhRMA’s board members are critical to driving forward policies that bolster innovation and improve patient access and affordability,” said Stephen Ubl, president and CEO of PhRMA. “I look forward to working with Jean-Michel in his new role as he takes the helm at Boehringer Ingelheim in the United States and continues the company’s legacy of leadership in the biopharmaceutical industry.”
Boers said, “The biopharmaceutical industry has an incredible impact on human health and society as a whole, perhaps now more than ever before. Today’s rapid pace of innovation in healthcare is driven by passionate, talented and committed men and women who are dedicated to help save lives. As a member of PhRMA’s board of directors, I will advocate for solutions to ensure continued scientific advancements and access to therapies for patients.”